27th week of 2009 patent applcation highlights part 44 |
Patent application number | Title | Published |
20090169489 | COBALAMIN COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING MUCOSITIS - The present invention relates to troches, patches, gels, or viscous liquids for topical treatment or prevention of mucosal surfaces containing as an active ingredient molecules of cobalamin for the treatment of inflammatory, ulcerative and painful conditions of mucosal surfaces such as mucositis, stomatitis, vestibulitis, aphthous ulcerations, and Behcet's syndrome. For reducing the incidence, duration, and pain levels of recurrent aphthous ulcers, bioactive cobalamin may delivered with adhering discs that stick to a tooth. | 2009-07-02 |
20090169490 | COMPOSITION AND METHOD FOR WEIGHT LOSS - A weight loss composition consisting of 1 to 10 weight parts of L-hydroxy citric acid and 1 to 10 weight parts of L-carnitine tartrate as active components, and pharmaceutically or food-acceptable carrier is disclosed. The present composition can be made to tablet, capsule, oral juice or chewing gum which shows great effect of weight loss. | 2009-07-02 |
20090169491 | Peptides Having Activities of Insulin Like Growth Factor-1 and their Uses - The present invention relates to a peptide having the activity of insulin like growth factor-1 (IGF-1) and derived from IGF-1, a composition for improving skin conditions or treating a periodontal disease comprising the peptide. The IGF-1 mimicking peptides of this invention have identical functions or actions to natural-occurring IGF-1 and much better stability and skin permeation than natural-occurring IGF-1. In these connections, the composition comprising the peptides of this invention can exhibit excellent efficacies on the treatment, prevention and improvement of diseases or conditions demanding IGF-1 activities. In addition, the peptides of this invention can be advantageously applied to pharmaceutical compositions, quasi-drugs and cosmetics. | 2009-07-02 |
20090169492 | Oral Cavity Composition - The object of the present invention is to provide an oral cavity composition which is nontoxic, excellent in plaque control, can prevent or treat onset of caries and periodontal disease caused by oral pathogens as well as can prevent or eliminate bad breath. The invention provides an oral cavity composition containing a lactic acid bacterium, | 2009-07-02 |
20090169493 | Anti-senstivity, anti-caries, anti-staining, anti-plaque, ultra-mild oral hygiene agent - This invention relates to a composition useful as a dentifrice comprising a surfactant agent consisting essentially of monoalkyl and dialkyl phosphate esters, wherein the ratio of monoesters to diesters is greater than 1, and optionally an abrasive agent consisting essentially of siliceous materials. | 2009-07-02 |
20090169494 | Sunscreen cosmetic composition - The present invention is a sunscreen cosmetic comprising 2,4-bis[[4-(2-ethylhexyloxy)-2-hydroxy]phenyl]-6-(4-methoxyphenyl)-1,3,5-triazine and a specific benzotriazole derivative. | 2009-07-02 |
20090169495 | Merocyanine Derivatives - Disclosed are merocyanine derivatives of formula (1), wherein R | 2009-07-02 |
20090169496 | Dispersion Of Microparticulate Titanium Oxide And Cosmetics Containing The Same - The present invention provides a dispersion of microparticulate titanium oxide that can generate a natural finish feeling, which includes a feeling of transparency, and has good long-term stability and an excellent UV protective effect in both UVA and UVB regions. The present invention is a dispersion of microparticulate titanium oxide characterized in that the microparticulate titanium oxide with the average major axis of 30 to 100 nm and the average minor axis of 8 to 50 nm is dispersed, by maintaining the average size of dispersed particles to be 80 to 110 nm, in a hydrophobic dispersion medium. In the dispersion of microparticulate titanium oxide, the content of silicone oil relative to the total hydrophobic dispersion medium is preferably 10 to 100 weight %. Furthermore, it is preferable that the dispersion of microparticulate titanium oxide contains a biterminally-siliconized polyglycerin as a dispersant. The dispersion of microparticulate titanium oxide can be preferably contained in a cosmetic. | 2009-07-02 |
20090169497 | Treatment and Prevention of Skin Injury Due to Exposure to Ultraviolet Light - Photoprotective agents useful for the treatment or prevention of cell damage, particularly skin injury due to UV-light. Methods of prevention or treatment of cell damage and skin injury due to exposure to UV-light, particularly UVB-light. Methods include administration of an effective amount of one or more photoprotective N-mercaptoalkanoylcysteine derivatives of this invention, particularly bucillamine or a salt or solvate thereof, to a mammal, particularly a human, which has been or will be exposed to UV-light. Administration may be oral, topical or parenteral. | 2009-07-02 |
20090169498 | Controlled Release Gels - The invention relates to the field of gel-based delivery systems for a compound of interest, like a drug or cosmetic agent. Provided is a gel comprising at least one nonpolymeric gelator and at least one polymer, wherein the polymer content of said gel is more than 5 weight percent (wt %), preferably at least 10 wt %, more preferably at least 20 wt %. Also provided is a method for preparing the gel and the use of the gel in a controlled delivery system, for example a pH-sensitive drug delivery system. | 2009-07-02 |
20090169499 | Interference pigments on the basis of silicon oxides - The present invention relates to pigments, the particles of which generally have a length of from 2 μm to 5 mm, a width of from 2 μm to 2 mm, and a thickness of from 20 nm to 2 μm, and a ratio of length to thickness of at least 2:1, wherein the particles contain a core of SiO | 2009-07-02 |
20090169500 | PERSONAL CARE COMPOSITIONS - This invention relates to personal care compositions containing polytrimethylene ether glycol in a variety of physical forms including solutions, gels, oil-in-water emulsions, water-in-oil emulsions, suspensions and solids. In a particularly preferred embodiment, the polytrimethylene ether glycol is derived predominantly from monomers obtained from renewable resources, making the personal care products of this embodiment of the present invention more environmentally friendly in terms of their manufacture, use and disposal. | 2009-07-02 |
20090169501 | MASCARA CONTAINING A SUGAR SILICONE SURFACTANT - The invention relates to a mascara composition comprising at least one sugar silicone surfactant, as well as to methods of making and using such mascaras. | 2009-07-02 |
20090169502 | COMPOSITIONS AND METHODS FOR TREATING KERATINOUS SUBSTRATES USING POLYAMIDES - The disclosure relates to compositions and methods of using the compositions to treat keratinous substrates. The compositions provide a water resistant and non-transferable protective barrier on the substrate. For example, the compositions provide hair with improved shine, condition, manageability and color. The compositions contain at least one polyamide, at least one monoacid, at least one water-insoluble ingredient, solvent and optionally at least one auxiliary ingredient. The methods for treating keratinous substrates involve contacting the keratinous substrates with the compositions of the disclosure. | 2009-07-02 |
20090169503 | DNA-BASED VACCINATION OF RETROVIRAL-INFECTED INDIVIDUALS UNDERGOING TREATMENT - This invention provides DNA vaccines for the treatment of patients undergoing retroviral therapy. The vaccines are surprisingly effective at controlling viremia. | 2009-07-02 |
20090169504 | Compounds and Pharmaceutical compositions for the treatment of Viral infections - Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. | 2009-07-02 |
20090169505 | NOVEL VACCINES AGAINST MULTIPLE SUBTYPES OF INFLUENZA VIRUS - An aspect of the present invention is directed towards DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of influenza virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient. The DNA plasmid is capable of expressing a consensus influenza antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal, wherein the consensus influenza antigen comprises consensus hemagglutinin (HA), neuraminidase (NA), matrix protein, nucleoprotein, M2 ectodomain-nucleo-protein (M2e-NP), or a combination thereof. Preferably the consensus influenza antigen comprises HA, NA, M2e-NP, or a combination thereof. The DNA plasmid comprises a promoter operably linked to a coding sequence that encodes the consensus influenza antigen. Additionally, an aspect of the present invention includes methods of eliciting an immune response against a plurality of influenza virus subtypes in a mammal using the DNA plasmid vaccines provided. | 2009-07-02 |
20090169506 | USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY - The invention relates to the use a substance signaling through gp130 for the manufacture of a medicament for the treatment and/or prevention of diabetic neuropathy. The use of IL-6 is preferred. | 2009-07-02 |
20090169507 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING FLAVIVIRIDAE INCLUDING HEPATITIS C - This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-HCV biologically active pentofuranonucleoside where the pentofuranonucleoside base is an optionally substituted 2-azapurine. The optionally substituted pentofuranonucleoside, or a salt or prodrug thereof, may be administered alone or in combination with one or more optionally substituted pentofuranonucleosides or other anti-viral agents. | 2009-07-02 |
20090169509 | O-linked glycosylation of peptides - The present invention provides polypeptides that include an O-linked glycosylation site that is not present in the wild-type peptide. The polypeptides of the invention include glycoconjugates in which a species such as a water-soluble polymer, a therapeutic agent of a biomolecule is covalently linked through an intact O-linked glycosyl residue to the polypeptide. Also provided are methods of making the peptides of the invention and methods, pharmaceutical compositions containing the peptides and methods of treating, ameliorating or preventing diseased in mammals by administering an amount of a peptide of the invention sufficient to achieve the desired response. | 2009-07-02 |
20090169510 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 2009-07-02 |
20090169511 | Mucosal Bioadhesive SLow Release Carrier for Delivering Active Principles - A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation. | 2009-07-02 |
20090169512 | VACCINIA VIRUS STRAINS - The invention provides attenuated vaccinia virus vaccines that can be used in methods to prevent or treat small pox in patients, as well as methods of obtaining such vaccines. | 2009-07-02 |
20090169513 | Expression of virus entry inhibitors and recombinant AAV therefor - The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver genes encoding human immunodeficiency virus entry inhibitors to target cells in mammals. | 2009-07-02 |
20090169514 | Expression Vectors Comprising the HS1 Promoter of the VAV1 Oncogene and Use Thereof for the Preparation of Pharmaceutical Compositions Intended for Somatic Gene Therapy - The present invention relates to the use of the HS1 promoter of the vav oncogene in the production of vectors selected from the groups of integrative vectors and non-integrative, non-plasmid vectors, for use in the preparation of pharmaceutical compositions intended for somatic gene therapy. By generating vectors that contain the HS1 promoter of the vav oncogene, it was possible to generate vectors in which the marker transgene or therapeutic transgene is expressed at moderate, but stable, levels in various cell lines both in vitro and in vivo. | 2009-07-02 |
20090169515 | Canine probiotic bifidobacteria globosum - According to the invention there is provided a strain of lactic acid bacteria of the species Bifidobacteria | 2009-07-02 |
20090169516 | METHOD OF CONSTRUCTING GENE TRANSPORT SUPPORT - An object of the present invention is to provide a method of efficiently constructing a gene delivery carrier having a favorable activity and expression efficiency of a protein expressed by a gene introduced by transformation. Moreover, an object of the present invention is to provide a pharmaceutical composition comprising a gene delivery carrier constructed by the construction method and a therapeutic agent for solid tumor comprising the resistant bacterium. The objects of the present invention have been attained by a gene delivery carrier consisting of an anaerobic microorganism capable of growing in a tumor tissue in an anaerobic environment and capable of expressing (A) a protein having an antitumor activity or (B) a protein having an activity of converting an antitumor substance precursor to an antitumor substance, wherein DNA encoding the protein of interest is allowed to further comprise, on the 5′-terminal side thereof, a DNA fragment comprising a nucleotide sequence encoding a peptide consisting of an amino acid sequence from the 1st to at least 4th amino acids at the N-terminus of a histone-like DNA-binding protein. | 2009-07-02 |
20090169517 | Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules - The present application discloses the preparation and use of attenuated tumor-targeted bacteria vectors for the delivery of one or more primary effector molecule(s) to the site of a solid tumor. The primary effector molecule(s) of the invention is used in the methods of the invention to treat a solid tumor cancer such as a carcinoma, melanoma, lymphoma, or sarcoma. The invention relates to the surprising discovery that effector molecules, which may be toxic when administered systemically to a host, can be delivered locally to tumors by attenuated tumor-targeted bacteria with reduced toxicity to the host. The application also discloses to the delivery of one or more optional effector molecule(s) (termed secondary effector molecules) which may be delivered by the attenuated tumor-targeted bacteria in conjunction with the primary effector molecule(s). | 2009-07-02 |
20090169518 | Pochonia chlamydosporia strain pcmr and method to use it in biological control of the root-knot-nematode (meloidogyne spp) - This invention refers to isolation and utilization of the fungus | 2009-07-02 |
20090169519 | MEDICINAL FORMULATION CONTAINING A COMBINATION OF HIV TYPE I AND HIV TYPE II - A novel medicinal formulation for the treatment of autoimmune diseases, said formulation comprising, combined serially diluted and potentized HIV TYPE I virus and HIV TYPE II virus, said dilution being effected in a vehicle selected from a group consisting of distilled water or ethyl alcohol and mixture of distilled water and ethyl alcohol. | 2009-07-02 |
20090169520 | Compounds, Pharmaceutical Compositions and Therapeutic Methods of Preventing and Treating Diseases and Disorders Associated With Amyloid Fibril Formation - Compounds, pharmaceutical compositions and methods for prevention and/or reversal of amyloid fibril formation and treating amyloid-related disorders are provided. Also provided a method of limiting and/or reducing inflammation. | 2009-07-02 |
20090169521 | Vascularized cardiac tissue and methods of producing and using same - An isolated composition of matter is disclosed. The composition comprises a heterogeneous population of cells seeded on a scaffold, wherein the heterogeneous population of cells comprises cardiomyocytes, endothelial cells and fibroblast cells. Pharmaceutical compositions comprising same and uses thereof are also disclosed. | 2009-07-02 |
20090169522 | MESENCHYMAL STEM CELLS EXPRESSING TNF-A RECEPTOR - Mesenchymal stem cells which express TNF-α receptor Type I in an amount of at least 13 pg/10 | 2009-07-02 |
20090169523 | HSC SELF-RENEWAL - The invention is related to methods for culturing stem cells, more particularly hematopoietic stem cells (HSC). The invention relates to methods for HSC expansion and the use of RASSF8 to increase the retention and/or expansion of KLS cells in vitro. The invention is also directed to cells produced by the methods of the invention. The cells are useful, among other things, for treatment of disorders or diseases (e.g. leukemia). The invention also relates to the development of small molecules that may increase HSC self renewal in vitro and in vivo. | 2009-07-02 |
20090169524 | COMPOSITES AND METHODS OF PREPARATION AND USE THEREOF - The invention provides composites, methods for their preparation, composites prepared according to the methods, and methods for using the composites. | 2009-07-02 |
20090169525 | METHODS OF REDUCING TRANSPLANT REJECTION AND CARDIAC ALLOGRAFT VASCULOPATHY BY IMPLANTING AUTOLOGOUS STEM CELLS - The invention provides novel methods of reducing transplant rejection and cardiac allograft vasculopathy in humans by employing the implantation of autologous progenitor cells into the transplanted donor heart. The autologous progenitor cells can be vascular progenitor cells (VPCs) and/or myocyte progenitor cells (MPCs) isolated from the recipient's explanted heart. Alternatively, bone marrow progenitor cells (BMPCs) isolated from the recipient may also be used. | 2009-07-02 |
20090169526 | BMP-6 ESTROGEN RESPONSIVE ELEMENT AND METHODS OF USE THEREOF - This invention is directed to a BMP-6 ERE nucleic acid sequence, vectors, cells and compositions comprising same. This invention also provides methods for identification of estrogen agonists, antagonists and therapeutic applications of same. This invention also provides methods of treating conditions, which are associated with estrogen insufficiency or with lack of response to external estrogen or agonists thereof utilizing sequences, vectors, cells and/or compositions described herein. | 2009-07-02 |
20090169527 | MATERIALS FROM BONE MARROW STROMAL CELLS FOR USE IN FORMING BLOOD VESSELS AND PRODUCING ANGIOGENIC AND TROPHIC FACTORS - A therapeutic for use in inducing angiogenesis and vasculogenesis, the therapeutic including angiogenesis and vasculogenesis inducing factors isolated from stem cells in conjunction with a pharmaceutically acceptable cell therapy. A method of amplifying the production of angiogenesis and vasculogenesis inducing factors secreted by exposing stem cells to and co-culturing the stem cells with a compound for increasing the production of angiogenesis and vasculogenesis inducing factors. Angiogenesis and vasculogenesis inducing factors isolated and purified from stem cells for use in a therapy. A process for obtaining the angiogenesis and vasculogenesis inducing factors as set forth above, the process including the steps of isolating and purifying human mesenchymal stem cells from tissue prior to differentiation and then culture expanding the mesenchymal stem cells to produce a tool for neurological and musculoskeletal therapy. Isolated and culture expanded mesenchymal stem cells under the influence of a requisite compound, that are capable of differentiating and producing a desired cell phenotype needed for tissue repair. | 2009-07-02 |
20090169528 | KERATINOCYTES EXPRESSING EXOGENOUS ANGIOGENIC GROWTH FACTORS - The present invention relates to in vitro cultured skin tissue, and in particular to cultured skin tissue comprising exogenous genes encoding angiogenic growth factors. In some embodiments, the keratinocytes express exogenous angiopoietin-1 or a member of the VEGF family, preferably VEGF-A. In particularly preferred embodiments, the keratinocytes are incorporated into cultured skin tissue. | 2009-07-02 |
20090169529 | COMPOSITIONS AND METHODS FOR IMMUNOSTIMULATORY RNA OLIGONUCLEOTIDES - The present invention provides 4-nucleotide (4mer) RNA motifs that confer immunostimulatory activity, in particular, IFN-α-inducing activity to a RNA oligonucleotide. The present invention also provides RNA oligonucleotides, including siRNA, with high or low immunostimulatory activity. The present invention further provides the use of the RNA oligonucleotides of the invention for therapeutic purposes. | 2009-07-02 |
20090169530 | Plant disease controlling agent and controlling method - A plant disease controlling agent containing a lactic acid bacterium which is capable of controlling plant disease and a plant disease controlling method which comprises treating a plant and/or soil with the above-mentioned lactic acid bacterium. By using the lactic acid bacterium seemingly advantageous to human health, an agricultural crop can be safely and stably produced. As the lactic acid bacterium as mentioned above, use may be favorably made of a microorganism belonging to the genus | 2009-07-02 |
20090169531 | Use of symbiotic for the treatment of atopic dermatitis - The invention relates to the use of a product comprising a living | 2009-07-02 |
20090169532 | CURABLE BONE CEMENT - The present invention describes a curable bone cement. The cement comprises a curable polymeric binder and a filler, and is capable of curing without substantial evolution of heat on exposure to a curing agent. The binder comprises phenol groups which are capable of reacting in order to cure the cement. | 2009-07-02 |
20090169533 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES - The present invention relates to compositions and methods for treating neurodegenerative diseases. In some embodiments, the present invention provides compositions for treating and preventing presbycusis. | 2009-07-02 |
20090169534 | Variant Forms of Urate Oxidase and Use Thereof - The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases. | 2009-07-02 |
20090169535 | TREATMENT OF EPILEPSY BY EXPRESSING ST3GAL-III - The present invention provides methods of diagnosing epilepsy in a mammal by detecting ST3 β-galactoside α-2,3-sialyltransferase 3 (ST3Gal-III) activity or by detecting for one or more mutations in a ST3Gal-III gene that decrease that activity of a ST3Gal-III polypeptide. The invention further provides methods of treating an epileptic condition associated with decreased ST3Gal-III activity by administering one or more agents that increase the activity of ST3Gal-III. Also provided are methods of identifying one or more agents that increase the activity of ST3Gal-III. | 2009-07-02 |
20090169536 | Polypeptide Having Phytase Activity and Nucleotide Sequence Encoding the Same - The invention relates to a recombinant DNA molecule, which, upon expression in a prokaryotic or eukaryotic host cell, encodes a polypeptide having phytase activity, wherein the recombinant DNA molecule comprises a DNA sequence selected from a) DNA sequences that have been obtained by variations of the mature wild-type | 2009-07-02 |
20090169537 | GLUTADON - The present invention relates to a pharmaceutical combination product for cancer therapy. The combination product comprises the two active ingredients glutaminase and 6-diazo-5-oxo-L-norleucine (DON). The invention further relates to the use of such a combination product for the treatment of cancers. | 2009-07-02 |
20090169538 | Methods of Treating or Preventing Tissue Damage Caused by Increased Blood Flow - A method of treating or preventing tissue damage occurring subsequent to affecting an increase in blood flow through a blood vessel which is in communication with the tissue, by administering an effective amount of a composition including a tissue damage-reducing or -preventing polypeptide including at least one of Thymosin beta 4 (TB4), an isoform of TB4, an N-terminal fragment of TB4, a C-terminal fragment of TB4, TB4 sulfoxide, an LKKTET [SEQ ID NO: 1] peptide, an LKKTNT [SEQ ID NO: 2] peptide, an actin-sequestering peptide, an actin binding peptide, an actin-mobilizing peptide, an actin polymerization-modulating peptide, or a conservative variant thereof having tissue damage-reducing activity. The composition is administered to the tissue before, during and/or after affecting the increase in blood flow. | 2009-07-02 |
20090169539 | PDGF FUSION PROTEINS INCORPORATED INTO FIBRIN FOAMS - Compositions for wound healing, use of the compositions, and kits and methods of using thereof are described herein. In a preferred aspect, the compositions are suitable for use in a method for forming a fibrin matrix or foam that can be applied or injected at the site of need. In another preferred aspect, the compositions are also suitable for use in methods for forming enhanced controlled delivery fibrin matrices that can be administered as gels or foams. | 2009-07-02 |
20090169540 | Use Of An Antagonist Of Epac For Treating Human Cardiac Hypertrophy - The present invention relates to the use of at least one Epac (Exchange Protein directly Activated by cAMP) antagonist for the manufacture of a medicament intended for the prevention or the treatment of pathologies selected from the list comprising cardiac hypertrophy, cardiac arrhythmias, valvulopathies, diastolic dysfunction, chronic heart failure, ischemic heart failure, and myocarditis. | 2009-07-02 |
20090169541 | Humanized Anti-CCR2 Antibodies and Methods of Use Therefor - The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods. | 2009-07-02 |
20090169542 | Modulators of neuronal regeneration - The present invention provides methods and compositions related to CNS function and diseases. | 2009-07-02 |
20090169543 | Method for regulating immune function in primates using the Foxp3 protein - Isolated nucleic acid molecules are provided which encode Fkh | 2009-07-02 |
20090169544 | FORMULATION - A stable, aqueous pharmaceutical composition comprising an antibody having a heavy chain amino acid sequence of SEQ ID No: 3 and a light chain amino acid sequence of SEQ ID No: 4 and a pharmaceutically-acceptable adjuvant, diluent, carrier or excipient, wherein said composition has a pH of 4 to 6. | 2009-07-02 |
20090169545 | 5-HT4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF HEART FAILURE - This invention provides the use of a 5-HT | 2009-07-02 |
20090169546 | HIGH AFFINITY ANTIBODIES AGAINST HMGB1 AND METHODS OF USE THEREOF - Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn s disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies. | 2009-07-02 |
20090169547 | MONOCLONAL ANTIBODIES AGAINST CLAUDIN-18 FOR TREATMENT OF CANCER - The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder. | 2009-07-02 |
20090169548 | BINDING MOLECULES - The present invention relates to the manufacture of mono, di and multivalent polypeptide binding complexes, also mono, di or multispecific polypeptide binding complexes and uses thereof. The invention also relates to the manufacture and use of a diverse repertoire of antigen specific VH binding domains derived from phage display libraries, transgenic animals or natural sources. Preferably the VH binding domains and the dimerisation domains comprise human sequences. The polypeptide binding complexes comprise homo or heterodimerisation domains with four antigen binding [VH] domains fused at the amino and carboxyl termini of the dimerisation domains preferably using natural hinge or linker peptides. Where the polypeptide binding complexes lack CH2-CH3 effector functions they are preferably less than 120 kDa in size. Routes of manufacture are described herein. | 2009-07-02 |
20090169549 | CONFORMATIONAL ISOMERS OF ALPHA-SYNUCLEIN, ANTIBODIES THERETO AND METHODS OF THEIR MANUFACTURE AND USE - Conformational isomers of modified versions of α-Synuclein (αSyn), a protein that is associated with Parkinson's disease, have been designed and produced. These conformational isomers are produced by introducing cysteines into the α-Synuclein and scrambling the disulfide bonds to form stable and immunogenic isomers. These isomers are generically referred to as X-isomers. X-αSyn is an X-isomer of αSyn. X-αSyn is generally more immunogenic than wt-αSyn. Two groups of X-αSyn have been produced. One group is 3-disulfide X-αSyn(3SS) produced by introducing 6 Cys mutations into the αSyn. The second group is 2-disulfide X-αSyn(2SS), produced by introducing 4 Cys mutations into the α-Syn. In each of these two groups of X-αSyn, Cys was introduced not only wt-αSyn, but also in two Parkinson Disease associated αSyn mutants, A30P-αSyn and A53T-αSyn. All six sets of X-αSyn exhibit enhanced aggregation as compared to wt-αSyn, and should therefore more much more immunogenic. It was discovered that refolding the proteins in a CuSO | 2009-07-02 |
20090169550 | THERAPY OF RITUXIMAB-REFRACTORY RHEUMATOID ARTHRITIS PATIENTS - A method is disclosed of treating a rituximab-refractory rheumatoid arthritis (RA) patient comprising administering an anti-CD20 antibody other than rituximab to the patient in an amount effective to treat the RA. | 2009-07-02 |
20090169551 | METHODS AND COMPOSITIONS FOR ACTIVATING OR INHIBITING VEGF-D AND VEGF-C - Methods for Activating endothelial growth factors VEGF-C or VEGF-D with plasmin, and methods of treatment comprising administering a pharmaceutical compositions comprising plasmin. Also disclosed are methods of screening for inhibitors of activation of the growth factors by plasmin, and method of treatment by blocking activation of VEGF-C/D activation by plasmin. Further disclosed are methods for screening for other proteases that activate VEGF-CD, and for inhibitors of such activation. The invention further includes inhibitors of plasmin activity and methods of treating patients in need thereof with said inhibitors. | 2009-07-02 |
20090169552 | NEGATIVE IMMUNOMODULATION OF IMMUNE RESPONSES BY ERp5 - The present invention relates to methods of treating immune disorders and cancers. In particular the invention provides methods of inhibiting the negative immunomodulatory effects of ERp-5 on T cells and dendritic cells, in conjunction with other surface receptors. | 2009-07-02 |
20090169553 | Novel Protein Fusion/Tag Technology - The present invention relates to fusion molecules comprising at least one first purification domain and a molecule of interest, wherein the purification domain is selected from the group consisting of a kringle domain and a staphylocoagulase D2 domain. The present invention further relates to methods of purifying a molecule of interest using the fusion molecules of the invention. Also provided is a method of making an antibody using the fusion molecules of the invention, wherein the purification domain is a kringle domain. In addition, the present invention provides for vaccines which have reduced immunoreactivity and which comprise a fusion molecule having a kringle domain and an immunogenic domain. | 2009-07-02 |
20090169554 | Polypeptides of Leishmania Major and Polynucleotides Encoding Same and Vaccinal, Therapeutical and Diagnostic Applications Thereof - The present invention relates to new proteins of | 2009-07-02 |
20090169555 | Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof - Nucleic acids encoding mouse and human sphingosine kinase type 2 isoforms, methods for detecting agents or drugs which inhibit or promote sphingosine activity and therapeutic agents containing peptides or antibodies to peptides encoded by such nucleic acids. | 2009-07-02 |
20090169556 | VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS - The present invention provides human vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that are useful for the treatment of age-related macular degeneration, and other diseases and disorders characterized by undesirable or excessive neovascularization. | 2009-07-02 |
20090169557 | Whole glucan particles in combination with antibiotics, vaccines and viral monoclonal antibodies - The present invention relates to compositions and methods of using whole glucan particles and agents. Whole glucan particles enhance the tumoricidal activity of the innate immune system by binding to the C3 complement protein receptor CR3. This binding enhances innate immune system cytotoxicity, as well as stimulating the release of activating cytokines and enhances the bodies response to the agent. | 2009-07-02 |
20090169558 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 - A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: | 2009-07-02 |
20090169559 | Parenteral formulations of peptides for the treatment of systemic lupus erythematosus - The subject invention provides a pharmaceutical composition comprising: an aqueous carrier; from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of a) a peptide comprising at least 12 and at most 30 consecutive amino acids having a sequence corresponding to (i) a sequence of amino acids found within a complementarity-determining region (CDR) of a heavy or a light chain of a human monoclonal anti-DNA 16/6 Id antibody, or (ii) a sequence of amino acids found within a complementarity-determining region (CDR) of a heavy or a light chain of a pathogenic anti-DNA monoclonal antibody that induces a systemic lupus erythematosus (SLE)-like disease response in mice, or b) a peptide comprising consecutive amino acids having the sequence shown by any of SEQ ID NOS. 8-17, or c) a peptide comprising consecutive amino acids having a sequence of any of a) and b), or at least two of the sequences in (a)(i), (a)(ii) and (b)(i) through (b)(x), or d) a peptide comprising consecutive amino acids having a sequence comprising at least two identical sequences included in (a)(i), (a)(ii) and (b)(i) through (b)(x); and a solubility enhancer, wherein both the peptide and the solubility enhancer are dissolved in the aqueous carrier; and wherein the composition has a pH between 4 and 9, and a method of alleviating symptoms of SLE in a human by administering an effective amount of the composition. | 2009-07-02 |
20090169560 | DISULFIDE, SULFIDE, SULFOXIDE, AND SULFONE DERIVATIVES OF CYCLIC SUGARS AND USES THEREOF - In the present invention there are disclosed new derivatives of dianhydrohexite mononitrate corresponding to formula (I), tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof: | 2009-07-02 |
20090169561 | Anti-IP-10 antibodies and methods of use thereof - The invention relates to fully human antibodies, and fragments thereof, that bind to interferon-inducible-protein-10 (IP-10, CXCL10), thereby modulating the interaction between IP-10 and its receptor, CXCR3, and/or modulating the biological activities of IP-10. The invention also relates to the use of such anti-IP-10 antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder. | 2009-07-02 |
20090169562 | Human Binding Molecules Having Killing Activity Against Enterococci and Uses Thereof - The present invention provides human binding molecules specifically binding to enterococci and having killing activity against enterococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and/or treatment of a condition resulting from | 2009-07-02 |
20090169563 | Antibodies to CD40 - The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies. The invention also relates to transgenic animals comprising nucleic acid molecules of the present invention. | 2009-07-02 |
20090169564 | Stimulus Inducible Protein Kinase Complex and Methods of Use Therefor - Compositions and methods are provided for treating NF-κB-related conditions. In particular, the invention provides a stimulus-inducible IKK signalsome, and components and variants thereof. An IKK signalsome or component thereof may be used, for example, to identify antibodies and other modulating agents that inhibit or activate signal transduction via the NF-κB cascade. IKK signalsome, components thereof and/or modulating agents may also be used for the treatment of diseases associated with NF-κB activation. | 2009-07-02 |
20090169565 | NEUTROKINE-ALPHA ANTIBODIES AND METHODS OF USE THEREOF - The present invention relates to a Neutrokine-alpha antibody and a process for producing a Neutrokine-alpha antibody. The invention further relates to screening methods for identifying compounds that inhibit or enhance the action of Neutrokine-alpha. Also provided are diagnostic methods for detecting autoimmune disorders and therapeutic methods for treating autoimmune disorders using a Neutrokine-alpha antibody. | 2009-07-02 |
20090169566 | BIOACTIVE COMPOSITIONS - This invention relates to a bioactive composition comprising: (d) pH sensitive bioactive agent (e) an edible carboxylic acid containing moiety and (f) an edible alkalising moiety, wherein the proportion of said moieties and active agent provide pH control such that (i) when 400 mg of said composition is added to 20 ml of 0.033 normal hydrochloric acid and at a temperature of 37+/−3° C., the pH reaches a value in the range 4 to 8, and (ii) when 400 mg of said composition is added to 20 ml of deionised water at pH 7 and at a temperature of 37+/−3° C., the pH reaches a value less than 8.5. | 2009-07-02 |
20090169567 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF - A compound represented by general formula (I): | 2009-07-02 |
20090169568 | Antigenic Complex for the Diagnosis and Treatment of Porphyromonas Gingivalis Infection - The present invention provides a purified multimeric complex form | 2009-07-02 |
20090169569 | APO-2L receptor agonist and CPT-11 synergism - Methods of using effective amounts of Apo-2L receptor agonists and CPT-11 to induce apoptosis and suppress growth of cancer cells are provided. | 2009-07-02 |
20090169570 | METHODS AND AGENTS FOR IMPROVING TARGETING OF CD138 EXPRESSING TUMOR CELLS - Disclosed are immunoconjugates having specificity for CD138 that diminish adhesion of CD138 expressing tumor cells to stroma cells and methods of using the same. This diminished adhesion renders the tumor cells not only susceptible to the immunoconjugate, but also to other agents, in particular cytotoxic agents. | 2009-07-02 |
20090169571 | SELECTED MA MOTIFS TO INCLUDE CELL DEATH AND/OR APOPTOSIS - The present application is directed to the use of dsRNA and/or ssRNA for the purpose of inducing apoptosis or cell death in proliferating cells. Specifically, low molecular weight and high molecular weight dsRNA and ssRNA are shown to induce apoptosis and/or cell death in proliferating cells, to arrest proliferation of transformed cells or tumor cells and to cause rapid induction of the cytokine TNF-alpha and/or also induce production of IL-12 which directs a Th-1 response. | 2009-07-02 |
20090169572 | METHODS FOR DAMAGING CELLS USING EFFECTOR FUNCTIONS OF ANTI-CDH3 ANTIBODIES - The present invention relates to the use of cytotoxicity based on the effector function of anti-CDH3 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient for damaging CDH3-expressing cells using antibody effector function. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present invention is useful in pancreatic, lung, colon, prostate, breast, gastric or liver cancer therapies. | 2009-07-02 |
20090169573 | T-Cell Stimulatory Peptides From The Melanoma-Associated Chondroitin Sulfate Proteoglycan And Their Use - The present invention relates to melanoma-associated chondroitin sulfate proteoglycan (MCSP) epitopes recognized by T cells, especially by CD4 | 2009-07-02 |
20090169574 | Heteroclitic analogs and related methods - Heteroclitic analogs of Class I epitopes are prepared by providing conservative or semi-conservative amino acid substitutions at positions 3 and/or 5 and/or 7 of these epitopes. The analogs are useful in eliciting immune responses with respect to the corresponding wildtype epitopes. | 2009-07-02 |
20090169575 | PROTEINS - The present invention provides methods and compositions for screening, diagnosis and prognosis of colorectal cancer, for monitoring the effectiveness of colorectal cancer treatment, and for drug development. | 2009-07-02 |
20090169576 | INFLUENZA COMBINATORIAL ANTIGEN VACCINE - The invention provides a combinatorial influenza vaccine composition for use in providing prophylactic protection in humans against influenza viruses or animals, and a method of producing the vaccine. | 2009-07-02 |
20090169577 | METHOD FOR STIMULATING IMMUNE RESPONSE AGAINST MORAXELLA CATARRHALIS - Provided is a method for stimulating in an individual an immune response against | 2009-07-02 |
20090169578 | TOLERIZING AGENTS - Described herein is the development of fusion proteins useful for inducing tolerance in a subject. In particular embodiments, the tolerizing agents are useful for influence autoimmune, inflammatory, and/or allergic reactions. Example tolerizing fusion proteins contain a targeting portion (which delivers the fusion protein) and a toleragen or allergen or other antigen to which tolerance is desired in a subject. In particular examples, it is demonstrated that a pσ1 fusion protein, when administered orally, facilitates systemic and mucosal tolerance. Also described is the nasal delivery of fusion proteins, for instance for restoring immunogenicity. | 2009-07-02 |
20090169579 | Modified vaccinia Ankara virus avriant - The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. | 2009-07-02 |
20090169580 | ATTENUATED VACCINES FOR NON-SEGMENTED NEGATIVE SENSE RNA VIRUSES - The invention relates to an attenuated non-segmented negative-sense RNA virus characterized by at least one mutation in the L gene wherein the mutation reduces viral replication, the methods of manufacturing and methods of use. | 2009-07-02 |
20090169581 | STABILIZING FORMULATIONS FOR RECOMBINANT VIRUSES - This invention relates to preparations of viruses, e.g. for vaccine or other pharmaceutical or research use, to their stabilization, and to processes of producing such preparations, as well as to their use, e.g. as vaccines or as virus vectors. The formulations comprise a sugar, a preservative, a dispersing agent, a thermal stability agent, a buffer, and up to three distinct types of amino acids without impacting the structural appearance of the lyophilized product. | 2009-07-02 |
20090169582 | RECOMBINANT LACTOBACILLUS AND USE OF THE SAME - The invention relates to recombinant | 2009-07-02 |
20090169583 | Solid Adsorbates of Hydrophobic Drugs - A solid pharmaceutical composition comprises a solid adsorbate comprising a hydrophobic drug, a lipophilic vehicle, and a porous substrate, wherein the hydrophobic drug and lipophilic vehicle are adsorbed to the porous substrate. | 2009-07-02 |
20090169584 | Treatment of sleep disturbances - The present invention provides a new composition for treating pain-associated sleep disturbances, especially shortened sleep duration, comprising ibuprofen and diphenhydramine. The composition is further prepared as a bilayer tablet or caplet, or alternatively as a soft gelatin capsule composition, to prevent interaction between the active ingredients. | 2009-07-02 |
20090169585 | Resveratrol-Containing Compositions And Their Use In Modulating Gene Product Concentration Or Activity - The present invention relates to a resveratrol-containing composition capable of modulating gene expression to an extent greater than that observed with resveratrol alone or with calorie restriction. The invention particularly pertains to such resveratrol-containing compositions that comprise resveratrol, a chelator, hyaluronic acid, and/or vitamin D and which upon administration to a recipient, increases the concentration or activity of a survival/longevity gene product and/or decreases the concentration or activity of a gene product that induces or causes cellular damage. Most preferably, the resveratrol-stabilizing composition will comprise the chelator phytic acid (inositol hexaphosphate; IP6), hyaluronic acid, and vitamin D. The invention further pertains to the use of such compositions in the treatment or prevention of cancer, cardiovascular disease, diseases associated with aging, and other conditions and illnesses. | 2009-07-02 |
20090169586 | STABLE PACKAGED DOSAGE FORM AND PROCESS THEREFOR - A process for preparing a stable packaged dosage form, said dosage form comprising an oxidation-sensitive material, for example carotenes and carotenoids in whole dried algae of the genus | 2009-07-02 |
20090169587 | Chronotherapeutic dosage forms - A chronotherapeutic pharmaceutical formulation comprising a core containing an active agent (e.g., a drug) and a surfactant and a delayed release compression coating comprising a natural or synthetic gum applied onto the surface of the core. | 2009-07-02 |
20090169588 | Compositions Containing Proteins for the Transfer/Recycling of Structurally Modified Lipids, and the Applications Thereof - The invention relates to compositions containing recycling/transfer proteins for structurally/functionally modified lipids, a lipid depot of structurally non-modified lipids, and non-transferable active ingredients. Such compositions can be used for the engineering of biomembranes, e.g. by external topical application, especially to the skin/mucous membranes. Structurally or functionally, especially oxidatively modified, lipids are removed from the structures containing the same, such as lipid aggregates of the skin, are externally regenerated in a depot, and preferably introduced back into the structures. The invention also relates to the recycling of modified lipids of biomembranes. The inventive compositions are self-regulative and can be especially applied in a cosmetic, cosmetic balneological or dermatological/pharmaceutical manner. | 2009-07-02 |
20090169589 | FILLER PIGMENTS - Filler pigments based on platelet-shaped substrates, which are coated with barium sulfate and at least two metal oxides and/or metal hydroxides are highly suitable as filler pigments especially for cosmetic formulations. | 2009-07-02 |